외적 환경을 고려한 최적의 항우울제 치료 = Optimising Antidepressant Use in Clinical Practice : Considering External Factors

다국어 초록 (Multilingual Abstract)

Depressive illness is a major public health problem with important medical, social and economic implications. The effcacy of various antidepressants in treating depression has been demonstrated in randomized controlled trials (RCTs). However, these studies do not adequately address the complexities of clinical practice. Although most of RCTs assumed there was no difference in effcacy between the tncyclic antidepressants (TCAs) and serotonin specific reuptake inhibitors (SSRIs), natumlistic studies show that patients who take TCAs often receive subtherapeutic doses for inadequate duration than those with SSRIs. Because the benefits of the implementation of current guidelines are limited, the optimal choice of medication must be guided by detailed history and careful consideration ofthe real-world efficacy of antidepressants and long-term health care costs.

참고문헌 (Reference)

1 Quitkin FM, "When should a trial of fluoxetine for major depression be declared failed?" 160 : 734-740, 2003

2 Altamura AC, "The use of antidepressants for long-term treatment of recurrent depression: rationale, current methodologies, and future directions" 54 : 29-37, 1993

3 Donoghue JM, "The treatment of depression: prescribing patterns of antidepressants in primary care in the UK" (168) : 164-168, 1996

4 Melfi CA, "The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression" 55 : 1128-1132, 1998

5 Greenberg PE, "The economic burden of depression in 1990" 54 : 405-418, 1990

6 Hughes CW, "The Texas Children’s Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder" 38 : 1442-1454, 1999

7 Altshuler LL, "The Expert Consensus Guideline Series. Treatment of depression in women" 1-107, 2001

8 Donoghue J, "Sub-optimal use of tricyclic antidepressants in primary care" 98 : 429-431, 1998

9 Weich S, "Somatic presentation of psychiatric morbidity in general practice" 45 : 143-147, 1995

10 Song F, "Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability" 306 : 683-687, 1993

11 Hylan TR, "SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis" 37 : 36-44, 1999

12 Paykel ES, "Recognition and management of depression in general practice: consensus statement" 305 : 1198-1202, 1992

13 Zetin M, "Rational antidepressant selection: applying evidence-based medicine to complex real-world patients" 39 : 38-104, 2006

14 Zetin M, "Rational antidepressant selection" 20 : 209-223, 1994

15 Bagby RM, "Psychosocial and clinical predictors of response to pharmacotherapy for depression" 27 : 250-257, 2002

16 "Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association" 157 : 1-45, 2000

17 Pampallona S, "Patient adherence in the treatment of depression" 180 : 104-109, 2002

18 "Paroxetine. a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group" 18 : 289-299, 1990

19 Mendlewicz J, "Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection" 42 : 1-3, 2001

20 Rost K, "Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care" 325 : 934-, 2002

21 Dunn RL, "Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines" 13 : 136-143, 1999

22 Simon GE, "Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants" 275 : 1897-1902, 1996

23 Hemels ME, "Increased use of antidepressants in Canada: 1981-2000" 36 : 1375-1379, 2000

24 Kwon JS, "How to choose the antidepressants in clinical practice?" 11 : 3-6, 2000

25 Sturm R, "How can care for depression become more costeffective?" 273 : 51-58, 1995

26 Simon G, "Health care costs associated with depressive and anxiety disorders in primary care" 152 : 352-357, 1995

27 Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology" 14 : 3-20, 2000

28 Llorca PM, "Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation" 61 : 702-710, 2007

29 Cramer JA, "Enhancing medication compliance for people with serious mental illness" 187 : 53-55, 1999

30 Arroll B, "Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis" 3 : 449-456, 2005

31 Thase ME, "Effectiveness of antidepressants: comparative remission rates" 64 (64): 3-7, 2003

32 Szegedi A, "Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression" 64 : 413-420, 2003

33 Chung S, "Does the use of SSRIs reduce medical care utilization and expenditures?" 8 : 119-129, 2005

34 Blacker CV, "Depressive disorder in primary care" 150 : 737-751, 1987

35 Greenberg PE, "Depression: a neglected major illness" 54 : 419-424, 1993

36 Lépine JP, "Depression in the community: the first pan-European study DEPRES (Depression Research in European Society)" 12 : 19-29, 1997

37 Hosák L, "Costs and outcomes of use of amitriptyline, citalopram and fluoxetine in major depression: exploratory study" 43 : 133-137, 2000

38 Priest RG, "Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients" 18 : 347-358, 1996

39 Simon G, "Cost-effectiveness comparisons using “real world” randomized trials: the case of new antidepressant drugs" 48 : 363-373, 1995

40 Kendrick T, "Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial" 188 : 337-345, 2006

41 Hatziandreu EJ, "Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin" 5 : 249-268, 1994

42 Trivedi MH, "Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder" 24 : 497-506, 2004

43 Prien RF, "Continuation drug therapy for major depressive episodes: how long should it be maintained?" 143 : 18-23, 1986

44 Fawcett J, "Compliance: definitions and key issues" 56 (56): 4-8, 1995

45 Demyttenaere K, "Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events" 62 (62): 30-33, 2001

46 "Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group" 90 : 131-138, 1986

47 Scott J, "Chronic depression" 153 : 287-297, 1988

48 Stewart A, "Choosing an antidepressant: effectiveness based pharmacoeconomics" 48 : 125-133, 1998

49 Zimmerman M, "Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?" 159 : 469-473, 2002

50 Donoghue J, "Antidepressant use in clinical practice: efficacy v. effectiveness" 42 : 9-17, 2001

51 MacDonald TM, "Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland" 313 : 860-861, 1996

52 François C, "A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway" 4 : 12-19, 2003

53 Doyle JJ, "A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs" 4 : 16-31, 2001

54 Einarson TR, "A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders" 17 : 136-153, 1995

55 Demyttenaere K, "A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium" 27 : 111-124, 2005

56 Leon AC, "A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness" 160 : 727-733, 2003